The role of non-selective beta-blockers in breast cancer treatment: an in vitro approach

Detalhes bibliográficos
Autor(a) principal: Pinho, Maria do Rosário Correia
Data de Publicação: 2022
Tipo de documento: Dissertação
Idioma: eng
Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Texto Completo: http://hdl.handle.net/10773/36515
Resumo: Breast cancer is the second most diagnosed type of cancer in the world and the fifth leading cause of death. Although it is more prevalent in women it can also affect men. Even though there are multiple treatment protocols, there is a need to develop more effective alternatives. The current study explored the effects on breast cancer cell lines, MCF-7 (metastatic cell line) and MDA-MB- 231 (non- metastatic), of pharmaceuticals like β-blockers already prescribed to treat other diseases. Thus, cells were exposed, up to 72h, to non-selective β- blockers, propranolol (10-250 μM) and carvedilol (0.1-100 μM), as well as to the antimetabolites already in use to treat cancer methotrexate (0.01-20 μM) and 5- fluorouracil (0.1-50 μM) and cell viability was assessed up to 72h exposure. The obtained results demonstrated higher sensitivity of MCF-7 to the tested drugs (carvedilol > propranolol > 5-fluorouracil > methotrexate). Based on the estimated medium lethal concentration, carvedilol was the most toxic drug followed by propranolol and cytostatic drugs. The obtained data support the potential application of beta-blockers in the treatment of breast cancer.
id RCAP_2767033e4dd1b595bb6a366056ec6758
oai_identifier_str oai:ria.ua.pt:10773/36515
network_acronym_str RCAP
network_name_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository_id_str 7160
spelling The role of non-selective beta-blockers in breast cancer treatment: an in vitro approachPropranololCarvedilolBeta-blockersBreast cancerBreast cancer is the second most diagnosed type of cancer in the world and the fifth leading cause of death. Although it is more prevalent in women it can also affect men. Even though there are multiple treatment protocols, there is a need to develop more effective alternatives. The current study explored the effects on breast cancer cell lines, MCF-7 (metastatic cell line) and MDA-MB- 231 (non- metastatic), of pharmaceuticals like β-blockers already prescribed to treat other diseases. Thus, cells were exposed, up to 72h, to non-selective β- blockers, propranolol (10-250 μM) and carvedilol (0.1-100 μM), as well as to the antimetabolites already in use to treat cancer methotrexate (0.01-20 μM) and 5- fluorouracil (0.1-50 μM) and cell viability was assessed up to 72h exposure. The obtained results demonstrated higher sensitivity of MCF-7 to the tested drugs (carvedilol > propranolol > 5-fluorouracil > methotrexate). Based on the estimated medium lethal concentration, carvedilol was the most toxic drug followed by propranolol and cytostatic drugs. The obtained data support the potential application of beta-blockers in the treatment of breast cancer.O cancro da mama é o segundo tipo de cancro mais diagnosticado em todo o mundo e a quinta principal casa de morte. Embora seja mais prevalente em mulheres, este também pode afetar homens. Apesar de existirem vários protocolos de tratamento, é necessário desenvolver alternativas mais eficazes. O presente estudo explorou os efeitos em linhas celulares de cancro da mama, MCF-7 (linha celular metastática) e MDA-MB-231 (linha celular não- metastática), de fármacos como beta-bloqueadores, que já são prescritos para o tratamento de outras doenças. Assim, as células foram expostas, até 72h, a β- bloqueadores não-seletivos, propranolol (10-250 μM) e carvedilol (0,1-100 μM) e também antimetabolítos já utilizados no tratamento de cancros, como o metotrexato (0,01- 20 μM) e o 5-fluorouracil (0,1-50 μM), avaliando as respetivas viabilidades celulares até a um máximo de 72 h de exposição. Os resultados obtidos demonstraram uma maior sensibilidade da linha MCF-7 aos fármacos testados (carvedilol > propranolol > 5-fluorouracil > metotrexato). Com base na análise da Dose Letal média, o carvedilol foi o fármaco que apresentou maior toxicidade para as células, seguido do propranolol e depois os medicamentos citostáticos. Os dados obtidos suportam a aplicação de beta- bloqueadores no tratamento de cancro da mama.2024-12-27T00:00:00Z2022-12-13T00:00:00Z2022-12-13info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/masterThesisapplication/pdfhttp://hdl.handle.net/10773/36515engPinho, Maria do Rosário Correiainfo:eu-repo/semantics/embargoedAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2024-02-22T12:10:23Zoai:ria.ua.pt:10773/36515Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-20T03:07:17.940710Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse
dc.title.none.fl_str_mv The role of non-selective beta-blockers in breast cancer treatment: an in vitro approach
title The role of non-selective beta-blockers in breast cancer treatment: an in vitro approach
spellingShingle The role of non-selective beta-blockers in breast cancer treatment: an in vitro approach
Pinho, Maria do Rosário Correia
Propranolol
Carvedilol
Beta-blockers
Breast cancer
title_short The role of non-selective beta-blockers in breast cancer treatment: an in vitro approach
title_full The role of non-selective beta-blockers in breast cancer treatment: an in vitro approach
title_fullStr The role of non-selective beta-blockers in breast cancer treatment: an in vitro approach
title_full_unstemmed The role of non-selective beta-blockers in breast cancer treatment: an in vitro approach
title_sort The role of non-selective beta-blockers in breast cancer treatment: an in vitro approach
author Pinho, Maria do Rosário Correia
author_facet Pinho, Maria do Rosário Correia
author_role author
dc.contributor.author.fl_str_mv Pinho, Maria do Rosário Correia
dc.subject.por.fl_str_mv Propranolol
Carvedilol
Beta-blockers
Breast cancer
topic Propranolol
Carvedilol
Beta-blockers
Breast cancer
description Breast cancer is the second most diagnosed type of cancer in the world and the fifth leading cause of death. Although it is more prevalent in women it can also affect men. Even though there are multiple treatment protocols, there is a need to develop more effective alternatives. The current study explored the effects on breast cancer cell lines, MCF-7 (metastatic cell line) and MDA-MB- 231 (non- metastatic), of pharmaceuticals like β-blockers already prescribed to treat other diseases. Thus, cells were exposed, up to 72h, to non-selective β- blockers, propranolol (10-250 μM) and carvedilol (0.1-100 μM), as well as to the antimetabolites already in use to treat cancer methotrexate (0.01-20 μM) and 5- fluorouracil (0.1-50 μM) and cell viability was assessed up to 72h exposure. The obtained results demonstrated higher sensitivity of MCF-7 to the tested drugs (carvedilol > propranolol > 5-fluorouracil > methotrexate). Based on the estimated medium lethal concentration, carvedilol was the most toxic drug followed by propranolol and cytostatic drugs. The obtained data support the potential application of beta-blockers in the treatment of breast cancer.
publishDate 2022
dc.date.none.fl_str_mv 2022-12-13T00:00:00Z
2022-12-13
2024-12-27T00:00:00Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/masterThesis
format masterThesis
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://hdl.handle.net/10773/36515
url http://hdl.handle.net/10773/36515
dc.language.iso.fl_str_mv eng
language eng
dc.rights.driver.fl_str_mv info:eu-repo/semantics/embargoedAccess
eu_rights_str_mv embargoedAccess
dc.format.none.fl_str_mv application/pdf
dc.source.none.fl_str_mv reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron:RCAAP
instname_str Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron_str RCAAP
institution RCAAP
reponame_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
collection Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository.name.fl_str_mv Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
repository.mail.fl_str_mv
_version_ 1799137728546209792

Registros relacionados